SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-041846
Filing Date
2024-04-04
Accepted
2024-04-04 16:30:21
Documents
13
Period of Report
2024-04-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-20240402.htm   iXBRL 8-K 49687
2 EX-10.1 abio-ex10_1.htm EX-10.1 110667
3 EX-10.2 abio-ex10_2.htm EX-10.2 113649
  Complete submission text file 0000950170-24-041846.txt   429228

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT abio-20240402.xsd EX-101.SCH 24886
16 EXTRACTED XBRL INSTANCE DOCUMENT abio-20240402_htm.xml XML 4679
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 24823499
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)